长期异基因造血干细胞移植幸存者接种疫苗后SARS-CoV-2 T细胞应答缺陷导致体液免疫减弱
该研究分析了50例未感染过新冠病毒的异基因造血干细胞移植受者(中位移植后92个月,范围7-340个月)和39名健康对照接种BNT162b2和mRNA-1273新冠疫苗后的安全性和免疫原性。结果显示,移植患者接种1剂后58%缺乏针对S1肽的T细胞应答,对照为19%(OR 0.17;P = .009);接种2剂后28%患者仍无特异性T细胞免疫,对照为6%(OR 0.18;P = .02)。接种后缺乏T细胞反应预示第二剂后5至6个月抗RBD-S1 IgG水平不足(<100 BAU/mL)(OR 8.2;P = .007)。
要点
- 异基因造血干细胞移植受者接种1剂后58%缺乏T细胞应答,对照为19%(OR 0.17;P = .009)
- 接种2剂后28%移植患者仍无特异性T细胞免疫,对照为6%(OR 0.18;P = .02)
- 缺乏T细胞反应预示第二剂后5至6个月抗RBD-S1 IgG不足(<100 BAU/mL)(OR 8.2;P = .007)
核心结论
- 异基因造血干细胞移植受者接种2剂新冠疫苗后可产生抗SARS-CoV-2 RBD-S1 IgG,但SARS-CoV-2特异性T细胞免疫缺陷可能随后导致体液应答不足。
研究设计与样本
- 研究分析了50例未感染过新冠病毒的异基因造血干细胞移植受者(中位移植后92个月,范围7-340个月)和39名健康对照接种BNT162b2和mRNA-1273新冠疫苗后的安全性和免疫原性。
主要发现
- 移植患者接种1剂后58%缺乏针对S1肽的T细胞应答,对照为19%(OR 0.17;P = .009,Fisher精确检验)。
- 移植患者接种2剂后28%仍无特异性T细胞免疫,对照为6%(OR 0.18;P = .02,Fisher精确检验)。
- 接种后缺乏对S1肽的T细胞反应预示第二剂后5至6个月抗RBD-S1 IgG水平不足(<100 BAU/mL)(OR 8.2;P = .007,Fisher精确检验)。
- 血清转阳率在移植患者与对照间无显著降低:第一剂后24%(12/50)患者保持血清阴性,第二剂后6%(3/50)患者保持血清阴性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for hematological diseases are at risk of severe disease and death from COVID-19. To determine the safety and immunogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines, samples from 50 infection-naive allo-HSCT recipients (median, 92 months from transplantation, range, 7-340 months) and 39 healthy controls were analyzed for serum immunoglobulin G (IgG) against the receptor binding domain (RBD) within spike 1 (S1) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; anti-RBD-S1 IgG) and for SARS-CoV-2-specific T-cell immunity, reflected by induction of T-cell-derived interferon-γ in whole blood stimulated ex vivo with 15-mer SI-spanning peptides with 11 amino acid overlap S1-spanning peptides. The rate of seroconversion was not significantly lower in allo-transplanted patients than in controls with 24% (12/50) and 6% (3/50) of patients remaining seronegative after the first and second vaccination, respectively. However, 58% of transplanted patients lacked T-cell responses against S1 peptides after 1 vaccination compared with 19% of controls (odds ratio [OR] 0.17; P = .009, Fisher's exact test) with a similar trend after the second vaccination where 28% of patients were devoid of detectable specific T-cell immunity, compared with 6% of controls (OR 0.18; P = .02, Fisher's exact test). Importantly, lack of T-cell reactivity to S1 peptides after vaccination heralded substandard levels (<100 BAU/mL) of anti-RBD-S1 IgG 5 to 6 months after the second vaccine dose (OR 8.2; P = .007, Fisher's exact test). We conclude that although allo-HSCT recipients achieve serum anti-RBD-S1 IgG against SARS-CoV-2 after 2 vaccinations, a deficiency of SARS-CoV-2-specific T-cell immunity may subsequently translate into insufficient humoral responses.
引用
- Einarsdottir S, Martner A, Waldenström J, et al. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Adv. 2022. PMID: 35286374. doi:10.1182/bloodadvances.2021006937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。